Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib

David F Heigener; Martin Reck

doi:10.1007/s12325-010-0096-4

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib

Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16.

Authors

David F Heigener¹, Martin Reck

Affiliation

¹ Hospital Grosshansdorf, Hamburg, Germany. D.Heigener@kh-grosshansdorf.de

PMID: 21181318
DOI: 10.1007/s12325-010-0096-4

Abstract

Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatment, is a problem of paramount importance. Several mechanisms of "acquired resistance" have been discovered and treatments for this specific entity are on the horizon.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Clinical Trials as Topic
Disease-Free Survival
Drug Resistance, Neoplasm
ErbB Receptors* / antagonists & inhibitors
ErbB Receptors* / genetics
Erlotinib Hydrochloride
Gefitinib
Genes, erbB-1*
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Molecular Targeted Therapy
Mutation
Protein Kinase Inhibitors / therapeutic use
Quinazolines / therapeutic use*

Substances

Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride
ErbB Receptors
Gefitinib